AAP
CRDF icon

Arax Advisory Partners’s Cardiff Oncology CRDF Stock Holding History

Arax Advisory Partners’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$551 Buy
340
+36
+12% +$74 ﹤0.01% 3399
2025
Q4 		$854 Sell
304
-558
-65% -$1.3K ﹤0.01% 3519
2025
Q3 		$1.77K Buy
862
+558
+184% +$1.54K ﹤0.01% 3140
2025
Q2 		$958 Buy
+304
New +$927 ﹤0.01% 2793

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return

Arax Advisory Partners's CRDF Position: Q1 2026 in Review

Arax Advisory Partners increased its Cardiff Oncology (CRDF) stake by 12% in Q1 2026, buying an estimated $74 and bringing the position to 340 shares worth $551. The position accounts for ﹤0.01% of the portfolio, ranked #3399.

Arax Advisory Partners first reported a position in CRDF in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.77K in Q3 2025. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2026.

  • Arax Advisory Partners held 340 shares of Cardiff Oncology worth $551 as of Q1 2026.
  • Arax Advisory Partners bought 36 Cardiff Oncology shares in Q1 2026, an estimated $74.
  • Cardiff Oncology made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3399 holding.
  • Arax Advisory Partners first reported a position in Cardiff Oncology in Q2 2025 and has held it in 4 quarters since.
  • Arax Advisory Partners's Cardiff Oncology position peaked at $1.77K in Q3 2025.
  • 116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.